nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—RPS6KB1—obesity	0.277	0.547	CbGaD
Crizotinib—TYK2—obesity	0.229	0.453	CbGaD
Crizotinib—CYP3A5—Cimetidine—obesity	0.00532	0.212	CbGbCtD
Crizotinib—CYP3A4—Sibutramine—obesity	0.00439	0.175	CbGbCtD
Crizotinib—ABCB1—Cimetidine—obesity	0.00346	0.138	CbGbCtD
Crizotinib—CYP3A4—Benzphetamine—obesity	0.00332	0.133	CbGbCtD
Crizotinib—CYP3A4—Bupropion—obesity	0.00283	0.113	CbGbCtD
Crizotinib—CYP3A4—Orlistat—obesity	0.0023	0.092	CbGbCtD
Crizotinib—CYP3A4—Cimetidine—obesity	0.00207	0.0828	CbGbCtD
Crizotinib—CYP3A4—Topiramate—obesity	0.00136	0.0542	CbGbCtD
Crizotinib—Dyspepsia—Methamphetamine—obesity	0.000733	0.00651	CcSEcCtD
Crizotinib—Vision blurred—Phenylpropanolamine—obesity	0.000722	0.00641	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Methamphetamine—obesity	0.000719	0.00639	CcSEcCtD
Crizotinib—Constipation—Methamphetamine—obesity	0.000712	0.00633	CcSEcCtD
Crizotinib—Bradycardia—Cimetidine—obesity	0.000709	0.00631	CcSEcCtD
Crizotinib—Hypophosphataemia—Topiramate—obesity	0.000709	0.0063	CcSEcCtD
Crizotinib—Dyspepsia—Benzphetamine—obesity	0.000707	0.00628	CcSEcCtD
Crizotinib—Fluid retention—Sibutramine—obesity	0.000704	0.00626	CcSEcCtD
Crizotinib—Decreased appetite—Benzphetamine—obesity	0.000698	0.0062	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Benzphetamine—obesity	0.000693	0.00616	CcSEcCtD
Crizotinib—Visual acuity reduced—Topiramate—obesity	0.000692	0.00615	CcSEcCtD
Crizotinib—Generalised oedema—Topiramate—obesity	0.000692	0.00615	CcSEcCtD
Crizotinib—Arrhythmia—Diethylpropion—obesity	0.000654	0.00582	CcSEcCtD
Crizotinib—Pulmonary embolism—Bupropion—obesity	0.000646	0.00575	CcSEcCtD
Crizotinib—Sepsis—Sibutramine—obesity	0.000643	0.00572	CcSEcCtD
Crizotinib—Decreased appetite—Phendimetrazine—obesity	0.000636	0.00565	CcSEcCtD
Crizotinib—Constipation—Phendimetrazine—obesity	0.000626	0.00556	CcSEcCtD
Crizotinib—Hepatic failure—Orlistat—obesity	0.000619	0.0055	CcSEcCtD
Crizotinib—Blood alkaline phosphatase increased—Sibutramine—obesity	0.000619	0.0055	CcSEcCtD
Crizotinib—Hepatic function abnormal—Sibutramine—obesity	0.000616	0.00547	CcSEcCtD
Crizotinib—Neuropathy—Bupropion—obesity	0.000607	0.00539	CcSEcCtD
Crizotinib—Photophobia—Bupropion—obesity	0.000607	0.00539	CcSEcCtD
Crizotinib—Vision blurred—Diethylpropion—obesity	0.000601	0.00534	CcSEcCtD
Crizotinib—Oedema—Phentermine—obesity	0.000598	0.00532	CcSEcCtD
Crizotinib—Burning sensation—Topiramate—obesity	0.000593	0.00527	CcSEcCtD
Crizotinib—Leukopenia—Diethylpropion—obesity	0.000571	0.00507	CcSEcCtD
Crizotinib—Diarrhoea—Methamphetamine—obesity	0.00057	0.00506	CcSEcCtD
Crizotinib—Dyspnoea—Phenylpropanolamine—obesity	0.000557	0.00495	CcSEcCtD
Crizotinib—Dizziness—Methamphetamine—obesity	0.000551	0.00489	CcSEcCtD
Crizotinib—Diarrhoea—Benzphetamine—obesity	0.000549	0.00488	CcSEcCtD
Crizotinib—Leukopenia—Cimetidine—obesity	0.000543	0.00483	CcSEcCtD
Crizotinib—Hepatic function abnormal—Bupropion—obesity	0.000537	0.00477	CcSEcCtD
Crizotinib—Constipation—Phenylpropanolamine—obesity	0.000535	0.00475	CcSEcCtD
Crizotinib—Dizziness—Benzphetamine—obesity	0.000531	0.00472	CcSEcCtD
Crizotinib—Dyspepsia—Phentermine—obesity	0.000527	0.00468	CcSEcCtD
Crizotinib—Face oedema—Sibutramine—obesity	0.00052	0.00462	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Phentermine—obesity	0.000516	0.00459	CcSEcCtD
Crizotinib—Fatigue—Phentermine—obesity	0.000516	0.00458	CcSEcCtD
Crizotinib—Constipation—Phentermine—obesity	0.000512	0.00455	CcSEcCtD
Crizotinib—Hypokalaemia—Orlistat—obesity	0.000506	0.0045	CcSEcCtD
Crizotinib—Diarrhoea—Phendimetrazine—obesity	0.000501	0.00445	CcSEcCtD
Crizotinib—Gamma-glutamyltransferase increased—Topiramate—obesity	0.000501	0.00445	CcSEcCtD
Crizotinib—Visual disturbance—Bupropion—obesity	0.000495	0.0044	CcSEcCtD
Crizotinib—Hypokalaemia—Sibutramine—obesity	0.00049	0.00435	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Sibutramine—obesity	0.000485	0.00431	CcSEcCtD
Crizotinib—Dizziness—Phendimetrazine—obesity	0.000484	0.0043	CcSEcCtD
Crizotinib—Nausea—Benzphetamine—obesity	0.000477	0.00424	CcSEcCtD
Crizotinib—Muscular weakness—Sibutramine—obesity	0.000475	0.00422	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Sibutramine—obesity	0.000475	0.00422	CcSEcCtD
Crizotinib—Diplopia—Bupropion—obesity	0.000469	0.00417	CcSEcCtD
Crizotinib—Dyspnoea—Diethylpropion—obesity	0.000464	0.00412	CcSEcCtD
Crizotinib—Dyspepsia—Diethylpropion—obesity	0.000458	0.00407	CcSEcCtD
Crizotinib—Face oedema—Bupropion—obesity	0.000453	0.00403	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Diethylpropion—obesity	0.000449	0.00399	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Orlistat—obesity	0.000447	0.00397	CcSEcCtD
Crizotinib—Constipation—Diethylpropion—obesity	0.000445	0.00395	CcSEcCtD
Crizotinib—Nausea—Phendimetrazine—obesity	0.000435	0.00386	CcSEcCtD
Crizotinib—Asthenia—Phentermine—obesity	0.000429	0.00381	CcSEcCtD
Crizotinib—Infestation NOS—Orlistat—obesity	0.000429	0.00381	CcSEcCtD
Crizotinib—Infestation—Orlistat—obesity	0.000429	0.00381	CcSEcCtD
Crizotinib—Fatigue—Cimetidine—obesity	0.000427	0.00379	CcSEcCtD
Crizotinib—Constipation—Cimetidine—obesity	0.000423	0.00376	CcSEcCtD
Crizotinib—Gait disturbance—Topiramate—obesity	0.000422	0.00375	CcSEcCtD
Crizotinib—Neuropathy peripheral—Orlistat—obesity	0.00042	0.00373	CcSEcCtD
Crizotinib—Pneumonia—Sibutramine—obesity	0.000417	0.00371	CcSEcCtD
Crizotinib—Muscular weakness—Bupropion—obesity	0.000414	0.00368	CcSEcCtD
Crizotinib—Dizziness—Phenylpropanolamine—obesity	0.000413	0.00367	CcSEcCtD
Crizotinib—Phosphatase alkaline increased—Topiramate—obesity	0.000412	0.00366	CcSEcCtD
Crizotinib—Pulmonary embolism—Topiramate—obesity	0.000412	0.00366	CcSEcCtD
Crizotinib—Diarrhoea—Phentermine—obesity	0.000409	0.00364	CcSEcCtD
Crizotinib—Neuropathy peripheral—Sibutramine—obesity	0.000407	0.00361	CcSEcCtD
Crizotinib—Hepatobiliary disease—Orlistat—obesity	0.000405	0.0036	CcSEcCtD
Crizotinib—Vomiting—Phenylpropanolamine—obesity	0.000397	0.00353	CcSEcCtD
Crizotinib—Dizziness—Phentermine—obesity	0.000396	0.00352	CcSEcCtD
Crizotinib—Rash—Phenylpropanolamine—obesity	0.000394	0.0035	CcSEcCtD
Crizotinib—Dermatitis—Phenylpropanolamine—obesity	0.000394	0.0035	CcSEcCtD
Crizotinib—Body temperature increased—Cimetidine—obesity	0.000391	0.00348	CcSEcCtD
Crizotinib—Fluid retention—Topiramate—obesity	0.000391	0.00347	CcSEcCtD
Crizotinib—Neuropathy—Topiramate—obesity	0.000387	0.00344	CcSEcCtD
Crizotinib—Photophobia—Topiramate—obesity	0.000387	0.00344	CcSEcCtD
Crizotinib—Vomiting—Phentermine—obesity	0.00038	0.00338	CcSEcCtD
Crizotinib—Urinary tract disorder—Orlistat—obesity	0.00038	0.00338	CcSEcCtD
Crizotinib—Bradycardia—Sibutramine—obesity	0.000379	0.00337	CcSEcCtD
Crizotinib—Oedema peripheral—Orlistat—obesity	0.000379	0.00337	CcSEcCtD
Crizotinib—Urethral disorder—Orlistat—obesity	0.000377	0.00335	CcSEcCtD
Crizotinib—Rash—Phentermine—obesity	0.000377	0.00335	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Bupropion—obesity	0.000377	0.00335	CcSEcCtD
Crizotinib—Dermatitis—Phentermine—obesity	0.000377	0.00335	CcSEcCtD
Crizotinib—Nausea—Phenylpropanolamine—obesity	0.000371	0.0033	CcSEcCtD
Crizotinib—Hypoaesthesia—Sibutramine—obesity	0.00037	0.00329	CcSEcCtD
Crizotinib—Weight decreased—Bupropion—obesity	0.000367	0.00326	CcSEcCtD
Crizotinib—Oedema peripheral—Sibutramine—obesity	0.000367	0.00326	CcSEcCtD
Crizotinib—Pneumonia—Bupropion—obesity	0.000364	0.00323	CcSEcCtD
Crizotinib—Infestation NOS—Bupropion—obesity	0.000362	0.00321	CcSEcCtD
Crizotinib—Infestation—Bupropion—obesity	0.000362	0.00321	CcSEcCtD
Crizotinib—Visual impairment—Sibutramine—obesity	0.000359	0.00319	CcSEcCtD
Crizotinib—Diarrhoea—Diethylpropion—obesity	0.000356	0.00316	CcSEcCtD
Crizotinib—Nausea—Phentermine—obesity	0.000355	0.00316	CcSEcCtD
Crizotinib—Asthenia—Cimetidine—obesity	0.000355	0.00316	CcSEcCtD
Crizotinib—Neuropathy peripheral—Bupropion—obesity	0.000354	0.00315	CcSEcCtD
Crizotinib—Eye disorder—Sibutramine—obesity	0.000348	0.00309	CcSEcCtD
Crizotinib—Mediastinal disorder—Orlistat—obesity	0.000347	0.00308	CcSEcCtD
Crizotinib—Dizziness—Diethylpropion—obesity	0.000344	0.00306	CcSEcCtD
Crizotinib—Blood alkaline phosphatase increased—Topiramate—obesity	0.000344	0.00305	CcSEcCtD
Crizotinib—Diarrhoea—Cimetidine—obesity	0.000339	0.00301	CcSEcCtD
Crizotinib—Malnutrition—Orlistat—obesity	0.000335	0.00298	CcSEcCtD
Crizotinib—Hepatic failure—Topiramate—obesity	0.000333	0.00296	CcSEcCtD
Crizotinib—Arrhythmia—Sibutramine—obesity	0.000333	0.00296	CcSEcCtD
Crizotinib—Vomiting—Diethylpropion—obesity	0.000331	0.00294	CcSEcCtD
Crizotinib—Rash—Diethylpropion—obesity	0.000328	0.00292	CcSEcCtD
Crizotinib—Dysgeusia—Orlistat—obesity	0.000328	0.00291	CcSEcCtD
Crizotinib—Dermatitis—Diethylpropion—obesity	0.000328	0.00291	CcSEcCtD
Crizotinib—Dizziness—Cimetidine—obesity	0.000327	0.00291	CcSEcCtD
Crizotinib—Malnutrition—Sibutramine—obesity	0.000324	0.00288	CcSEcCtD
Crizotinib—Hypoaesthesia—Bupropion—obesity	0.000323	0.00287	CcSEcCtD
Crizotinib—Urinary tract disorder—Bupropion—obesity	0.000321	0.00285	CcSEcCtD
Crizotinib—Oedema peripheral—Bupropion—obesity	0.00032	0.00284	CcSEcCtD
Crizotinib—Urethral disorder—Bupropion—obesity	0.000318	0.00283	CcSEcCtD
Crizotinib—Dysgeusia—Sibutramine—obesity	0.000317	0.00282	CcSEcCtD
Crizotinib—Vision blurred—Orlistat—obesity	0.000316	0.00281	CcSEcCtD
Crizotinib—Visual disturbance—Topiramate—obesity	0.000315	0.0028	CcSEcCtD
Crizotinib—Vomiting—Cimetidine—obesity	0.000315	0.0028	CcSEcCtD
Crizotinib—YES1—respiratory system—obesity	0.000314	0.0023	CbGeAlD
Crizotinib—Visual impairment—Bupropion—obesity	0.000313	0.00278	CcSEcCtD
Crizotinib—Rash—Cimetidine—obesity	0.000312	0.00277	CcSEcCtD
Crizotinib—AXL—adrenal cortex—obesity	0.000312	0.00229	CbGeAlD
Crizotinib—Dermatitis—Cimetidine—obesity	0.000312	0.00277	CcSEcCtD
Crizotinib—STK10—respiratory system—obesity	0.000311	0.00228	CbGeAlD
Crizotinib—EPHA6—endocrine gland—obesity	0.00031	0.00227	CbGeAlD
Crizotinib—JAK3—endocrine gland—obesity	0.00031	0.00227	CbGeAlD
Crizotinib—TAOK3—respiratory system—obesity	0.00031	0.00227	CbGeAlD
Crizotinib—STK3—adrenal gland—obesity	0.00031	0.00227	CbGeAlD
Crizotinib—TIE1—adrenal gland—obesity	0.00031	0.00227	CbGeAlD
Crizotinib—Nausea—Diethylpropion—obesity	0.000309	0.00275	CcSEcCtD
Crizotinib—DCLK1—endocrine gland—obesity	0.000308	0.00226	CbGeAlD
Crizotinib—STK35—adipose tissue—obesity	0.000308	0.00226	CbGeAlD
Crizotinib—CDK7—liver—obesity	0.000307	0.00225	CbGeAlD
Crizotinib—PLK4—endocrine gland—obesity	0.000306	0.00224	CbGeAlD
Crizotinib—Vision blurred—Sibutramine—obesity	0.000305	0.00271	CcSEcCtD
Crizotinib—STK4—endocrine gland—obesity	0.000304	0.00223	CbGeAlD
Crizotinib—TAOK2—liver—obesity	0.000304	0.00223	CbGeAlD
Crizotinib—Eye disorder—Bupropion—obesity	0.000303	0.0027	CcSEcCtD
Crizotinib—SRC—respiratory system—obesity	0.000302	0.00221	CbGeAlD
Crizotinib—AURKA—adrenal gland—obesity	0.000302	0.00221	CbGeAlD
Crizotinib—ABL2—pituitary gland—obesity	0.000301	0.00221	CbGeAlD
Crizotinib—Cardiac disorder—Bupropion—obesity	0.000301	0.00268	CcSEcCtD
Crizotinib—SLK—adrenal cortex—obesity	0.0003	0.0022	CbGeAlD
Crizotinib—ABL2—adipose tissue—obesity	0.0003	0.0022	CbGeAlD
Crizotinib—Anaemia—Sibutramine—obesity	0.0003	0.00266	CcSEcCtD
Crizotinib—TESK1—adrenal gland—obesity	0.0003	0.0022	CbGeAlD
Crizotinib—Diplopia—Topiramate—obesity	0.000299	0.00266	CcSEcCtD
Crizotinib—PTK2—cardiovascular system—obesity	0.000299	0.00219	CbGeAlD
Crizotinib—TBK1—cardiovascular system—obesity	0.000299	0.00219	CbGeAlD
Crizotinib—EPHB4—adrenal cortex—obesity	0.000298	0.00219	CbGeAlD
Crizotinib—TYK2—cardiovascular system—obesity	0.000297	0.00218	CbGeAlD
Crizotinib—BMP2K—adipose tissue—obesity	0.000296	0.00217	CbGeAlD
Crizotinib—Nausea—Cimetidine—obesity	0.000294	0.00261	CcSEcCtD
Crizotinib—ACVR1B—liver—obesity	0.000293	0.00215	CbGeAlD
Crizotinib—Mediastinal disorder—Bupropion—obesity	0.000293	0.0026	CcSEcCtD
Crizotinib—EPHA2—adrenal cortex—obesity	0.000292	0.00214	CbGeAlD
Crizotinib—MERTK—adrenal gland—obesity	0.000291	0.00214	CbGeAlD
Crizotinib—Syncope—Sibutramine—obesity	0.000291	0.00258	CcSEcCtD
Crizotinib—Leukopenia—Sibutramine—obesity	0.00029	0.00258	CcSEcCtD
Crizotinib—Arrhythmia—Bupropion—obesity	0.00029	0.00258	CcSEcCtD
Crizotinib—Face oedema—Topiramate—obesity	0.000289	0.00256	CcSEcCtD
Crizotinib—RPS6KB1—cardiovascular system—obesity	0.000288	0.00211	CbGeAlD
Crizotinib—TYRO3—endocrine gland—obesity	0.000288	0.00211	CbGeAlD
Crizotinib—ALK—endocrine gland—obesity	0.000288	0.00211	CbGeAlD
Crizotinib—FER—endocrine gland—obesity	0.000288	0.00211	CbGeAlD
Crizotinib—EPHA5—endocrine gland—obesity	0.000288	0.00211	CbGeAlD
Crizotinib—PTK2B—adipose tissue—obesity	0.000286	0.0021	CbGeAlD
Crizotinib—LYN—endocrine gland—obesity	0.000286	0.0021	CbGeAlD
Crizotinib—FGR—cardiovascular system—obesity	0.000286	0.0021	CbGeAlD
Crizotinib—TEK—adrenal cortex—obesity	0.000285	0.00209	CbGeAlD
Crizotinib—MAP3K3—adrenal cortex—obesity	0.000285	0.00209	CbGeAlD
Crizotinib—RIPK2—pituitary gland—obesity	0.000285	0.00209	CbGeAlD
Crizotinib—LIMK2—adrenal gland—obesity	0.000285	0.00209	CbGeAlD
Crizotinib—Loss of consciousness—Sibutramine—obesity	0.000285	0.00253	CcSEcCtD
Crizotinib—AXL—cardiovascular system—obesity	0.000285	0.00209	CbGeAlD
Crizotinib—TNK1—endocrine gland—obesity	0.000285	0.00209	CbGeAlD
Crizotinib—NUAK2—adrenal gland—obesity	0.000284	0.00208	CbGeAlD
Crizotinib—RIPK2—adipose tissue—obesity	0.000284	0.00208	CbGeAlD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Orlistat—obesity	0.000283	0.00252	CcSEcCtD
Crizotinib—Malnutrition—Bupropion—obesity	0.000283	0.00251	CcSEcCtD
Crizotinib—FLT3—adrenal gland—obesity	0.000282	0.00207	CbGeAlD
Crizotinib—MAP3K12—adrenal gland—obesity	0.000282	0.00207	CbGeAlD
Crizotinib—ACVR1—adrenal gland—obesity	0.000282	0.00207	CbGeAlD
Crizotinib—BMPR1B—endocrine gland—obesity	0.000282	0.00206	CbGeAlD
Crizotinib—Dysgeusia—Bupropion—obesity	0.000277	0.00246	CcSEcCtD
Crizotinib—TNK2—endocrine gland—obesity	0.000276	0.00202	CbGeAlD
Crizotinib—IGF1R—endocrine gland—obesity	0.000276	0.00202	CbGeAlD
Crizotinib—STK35—adrenal gland—obesity	0.000276	0.00202	CbGeAlD
Crizotinib—EPHA4—pituitary gland—obesity	0.000276	0.00202	CbGeAlD
Crizotinib—EPHA4—adipose tissue—obesity	0.000274	0.00201	CbGeAlD
Crizotinib—STK4—liver—obesity	0.000274	0.00201	CbGeAlD
Crizotinib—Oedema—Orlistat—obesity	0.000273	0.00243	CcSEcCtD
Crizotinib—MAP4K2—endocrine gland—obesity	0.000272	0.002	CbGeAlD
Crizotinib—Hypokalaemia—Topiramate—obesity	0.000272	0.00242	CcSEcCtD
Crizotinib—EPHB4—cardiovascular system—obesity	0.000272	0.00199	CbGeAlD
Crizotinib—Infection—Orlistat—obesity	0.000272	0.00241	CcSEcCtD
Crizotinib—CSF1R—respiratory system—obesity	0.000271	0.00199	CbGeAlD
Crizotinib—JAK2—cardiovascular system—obesity	0.00027	0.00198	CbGeAlD
Crizotinib—PTK2B—digestive system—obesity	0.000269	0.00198	CbGeAlD
Crizotinib—Aspartate aminotransferase increased—Topiramate—obesity	0.000269	0.00239	CcSEcCtD
Crizotinib—ABL2—adrenal gland—obesity	0.000269	0.00197	CbGeAlD
Crizotinib—MAP3K2—adipose tissue—obesity	0.000269	0.00197	CbGeAlD
Crizotinib—Nervous system disorder—Orlistat—obesity	0.000268	0.00238	CcSEcCtD
Crizotinib—RIPK2—digestive system—obesity	0.000267	0.00196	CbGeAlD
Crizotinib—EPHA2—cardiovascular system—obesity	0.000267	0.00196	CbGeAlD
Crizotinib—Vision blurred—Bupropion—obesity	0.000266	0.00237	CcSEcCtD
Crizotinib—BMP2K—adrenal gland—obesity	0.000266	0.00195	CbGeAlD
Crizotinib—Skin disorder—Orlistat—obesity	0.000266	0.00236	CcSEcCtD
Crizotinib—PTK2—pituitary gland—obesity	0.000265	0.00194	CbGeAlD
Crizotinib—TBK1—pituitary gland—obesity	0.000265	0.00194	CbGeAlD
Crizotinib—Oedema—Sibutramine—obesity	0.000265	0.00235	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Topiramate—obesity	0.000264	0.00234	CcSEcCtD
Crizotinib—Muscular weakness—Topiramate—obesity	0.000264	0.00234	CcSEcCtD
Crizotinib—PTK2—adipose tissue—obesity	0.000264	0.00193	CbGeAlD
Crizotinib—TBK1—adipose tissue—obesity	0.000264	0.00193	CbGeAlD
Crizotinib—YES1—adrenal cortex—obesity	0.000263	0.00193	CbGeAlD
Crizotinib—TYK2—pituitary gland—obesity	0.000263	0.00193	CbGeAlD
Crizotinib—Infection—Sibutramine—obesity	0.000263	0.00234	CcSEcCtD
Crizotinib—AURKA—endocrine gland—obesity	0.000262	0.00192	CbGeAlD
Crizotinib—TYK2—adipose tissue—obesity	0.000262	0.00192	CbGeAlD
Crizotinib—Anaemia—Bupropion—obesity	0.000261	0.00232	CcSEcCtD
Crizotinib—MAP3K3—cardiovascular system—obesity	0.00026	0.00191	CbGeAlD
Crizotinib—TEK—cardiovascular system—obesity	0.00026	0.00191	CbGeAlD
Crizotinib—Shock—Sibutramine—obesity	0.00026	0.00231	CcSEcCtD
Crizotinib—TAOK3—adrenal cortex—obesity	0.00026	0.00191	CbGeAlD
Crizotinib—TESK1—endocrine gland—obesity	0.00026	0.0019	CbGeAlD
Crizotinib—FER—liver—obesity	0.000259	0.0019	CbGeAlD
Crizotinib—IRAK1—adipose tissue—obesity	0.000258	0.00189	CbGeAlD
Crizotinib—LYN—liver—obesity	0.000258	0.00189	CbGeAlD
Crizotinib—Skin disorder—Sibutramine—obesity	0.000257	0.00228	CcSEcCtD
Crizotinib—PTK2B—adrenal gland—obesity	0.000257	0.00188	CbGeAlD
Crizotinib—TNK1—liver—obesity	0.000257	0.00188	CbGeAlD
Crizotinib—RIPK2—adrenal gland—obesity	0.000255	0.00187	CbGeAlD
Crizotinib—RPS6KB1—pituitary gland—obesity	0.000255	0.00187	CbGeAlD
Crizotinib—RPS6KB1—adipose tissue—obesity	0.000254	0.00186	CbGeAlD
Crizotinib—Syncope—Bupropion—obesity	0.000253	0.00225	CcSEcCtD
Crizotinib—FGR—pituitary gland—obesity	0.000253	0.00186	CbGeAlD
Crizotinib—Leukopenia—Bupropion—obesity	0.000253	0.00225	CcSEcCtD
Crizotinib—MERTK—endocrine gland—obesity	0.000253	0.00185	CbGeAlD
Crizotinib—AXL—pituitary gland—obesity	0.000252	0.00185	CbGeAlD
Crizotinib—LCK—adipose tissue—obesity	0.000252	0.00185	CbGeAlD
Crizotinib—FGR—adipose tissue—obesity	0.000252	0.00185	CbGeAlD
Crizotinib—AXL—adipose tissue—obesity	0.000251	0.00184	CbGeAlD
Crizotinib—TNK2—liver—obesity	0.000249	0.00183	CbGeAlD
Crizotinib—IGF1R—liver—obesity	0.000249	0.00183	CbGeAlD
Crizotinib—Loss of consciousness—Bupropion—obesity	0.000248	0.00221	CcSEcCtD
Crizotinib—TBK1—digestive system—obesity	0.000248	0.00182	CbGeAlD
Crizotinib—PTK2—digestive system—obesity	0.000248	0.00182	CbGeAlD
Crizotinib—LIMK2—endocrine gland—obesity	0.000247	0.00181	CbGeAlD
Crizotinib—TYK2—digestive system—obesity	0.000246	0.00181	CbGeAlD
Crizotinib—EPHA4—adrenal gland—obesity	0.000246	0.0018	CbGeAlD
Crizotinib—MAP4K2—liver—obesity	0.000246	0.0018	CbGeAlD
Crizotinib—Paraesthesia—Orlistat—obesity	0.000245	0.00218	CcSEcCtD
Crizotinib—MAP3K12—endocrine gland—obesity	0.000244	0.00179	CbGeAlD
Crizotinib—ACVR1—endocrine gland—obesity	0.000244	0.00179	CbGeAlD
Crizotinib—FLT3—endocrine gland—obesity	0.000244	0.00179	CbGeAlD
Crizotinib—SLK—pituitary gland—obesity	0.000243	0.00178	CbGeAlD
Crizotinib—STK3—liver—obesity	0.000242	0.00178	CbGeAlD
Crizotinib—TIE1—liver—obesity	0.000242	0.00178	CbGeAlD
Crizotinib—SLK—adipose tissue—obesity	0.000242	0.00177	CbGeAlD
Crizotinib—Neutropenia—Topiramate—obesity	0.000242	0.00215	CcSEcCtD
Crizotinib—MAP3K2—adrenal gland—obesity	0.000241	0.00177	CbGeAlD
Crizotinib—EPHB4—pituitary gland—obesity	0.000241	0.00177	CbGeAlD
Crizotinib—Dyspepsia—Orlistat—obesity	0.000241	0.00214	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Topiramate—obesity	0.00024	0.00213	CcSEcCtD
Crizotinib—EPHB4—adipose tissue—obesity	0.00024	0.00176	CbGeAlD
Crizotinib—STK35—endocrine gland—obesity	0.00024	0.00176	CbGeAlD
Crizotinib—JAK2—pituitary gland—obesity	0.000239	0.00175	CbGeAlD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Bupropion—obesity	0.000239	0.00212	CcSEcCtD
Crizotinib—RPS6KB1—digestive system—obesity	0.000239	0.00175	CbGeAlD
Crizotinib—STK10—cardiovascular system—obesity	0.000238	0.00175	CbGeAlD
Crizotinib—JAK2—adipose tissue—obesity	0.000238	0.00175	CbGeAlD
Crizotinib—Decreased appetite—Orlistat—obesity	0.000238	0.00211	CcSEcCtD
Crizotinib—Paraesthesia—Sibutramine—obesity	0.000238	0.00211	CcSEcCtD
Crizotinib—TAOK3—cardiovascular system—obesity	0.000237	0.00174	CbGeAlD
Crizotinib—FGR—digestive system—obesity	0.000237	0.00174	CbGeAlD
Crizotinib—TBK1—adrenal gland—obesity	0.000236	0.00173	CbGeAlD
Crizotinib—PTK2—adrenal gland—obesity	0.000236	0.00173	CbGeAlD
Crizotinib—EPHA2—pituitary gland—obesity	0.000236	0.00173	CbGeAlD
Crizotinib—AURKA—liver—obesity	0.000236	0.00173	CbGeAlD
Crizotinib—Gastrointestinal disorder—Orlistat—obesity	0.000236	0.0021	CcSEcCtD
Crizotinib—Dyspnoea—Sibutramine—obesity	0.000236	0.0021	CcSEcCtD
Crizotinib—Fatigue—Orlistat—obesity	0.000236	0.00209	CcSEcCtD
Crizotinib—EPHA2—adipose tissue—obesity	0.000235	0.00173	CbGeAlD
Crizotinib—TYK2—adrenal gland—obesity	0.000235	0.00172	CbGeAlD
Crizotinib—TESK1—liver—obesity	0.000234	0.00172	CbGeAlD
Crizotinib—Weight decreased—Topiramate—obesity	0.000234	0.00208	CcSEcCtD
Crizotinib—Dyspepsia—Sibutramine—obesity	0.000233	0.00207	CcSEcCtD
Crizotinib—IRAK1—adrenal gland—obesity	0.000232	0.0017	CbGeAlD
Crizotinib—Pneumonia—Topiramate—obesity	0.000232	0.00206	CcSEcCtD
Crizotinib—SRC—cardiovascular system—obesity	0.000231	0.0017	CbGeAlD
Crizotinib—Oedema—Bupropion—obesity	0.000231	0.00205	CcSEcCtD
Crizotinib—BMP2K—endocrine gland—obesity	0.000231	0.00169	CbGeAlD
Crizotinib—MAP4K5—pituitary gland—obesity	0.000231	0.00169	CbGeAlD
Crizotinib—TEK—pituitary gland—obesity	0.000231	0.00169	CbGeAlD
Crizotinib—MAP3K3—pituitary gland—obesity	0.000231	0.00169	CbGeAlD
Crizotinib—Infestation—Topiramate—obesity	0.00023	0.00205	CcSEcCtD
Crizotinib—Infestation NOS—Topiramate—obesity	0.00023	0.00205	CcSEcCtD
Crizotinib—Decreased appetite—Sibutramine—obesity	0.00023	0.00204	CcSEcCtD
Crizotinib—MAP3K3—adipose tissue—obesity	0.00023	0.00168	CbGeAlD
Crizotinib—TEK—adipose tissue—obesity	0.00023	0.00168	CbGeAlD
Crizotinib—MAP4K5—adipose tissue—obesity	0.00023	0.00168	CbGeAlD
Crizotinib—Infection—Bupropion—obesity	0.000229	0.00204	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Sibutramine—obesity	0.000228	0.00203	CcSEcCtD
Crizotinib—MERTK—liver—obesity	0.000228	0.00167	CbGeAlD
Crizotinib—CSF1R—adrenal cortex—obesity	0.000228	0.00167	CbGeAlD
Crizotinib—RPS6KB1—adrenal gland—obesity	0.000227	0.00167	CbGeAlD
Crizotinib—ABL1—islet of Langerhans—obesity	0.000227	0.00166	CbGeAlD
Crizotinib—Shock—Bupropion—obesity	0.000227	0.00202	CcSEcCtD
Crizotinib—Constipation—Sibutramine—obesity	0.000226	0.00201	CcSEcCtD
Crizotinib—Nervous system disorder—Bupropion—obesity	0.000226	0.00201	CcSEcCtD
Crizotinib—FGR—adrenal gland—obesity	0.000226	0.00166	CbGeAlD
Crizotinib—LCK—adrenal gland—obesity	0.000226	0.00166	CbGeAlD
Crizotinib—EPHB4—digestive system—obesity	0.000226	0.00166	CbGeAlD
Crizotinib—Neuropathy peripheral—Topiramate—obesity	0.000226	0.00201	CcSEcCtD
Crizotinib—AXL—adrenal gland—obesity	0.000225	0.00165	CbGeAlD
Crizotinib—JAK2—digestive system—obesity	0.000224	0.00164	CbGeAlD
Crizotinib—Skin disorder—Bupropion—obesity	0.000224	0.00199	CcSEcCtD
Crizotinib—LIMK2—liver—obesity	0.000223	0.00163	CbGeAlD
Crizotinib—PTK2B—endocrine gland—obesity	0.000223	0.00163	CbGeAlD
Crizotinib—NUAK2—liver—obesity	0.000222	0.00163	CbGeAlD
Crizotinib—EPHA2—digestive system—obesity	0.000222	0.00162	CbGeAlD
Crizotinib—RIPK2—endocrine gland—obesity	0.000221	0.00162	CbGeAlD
Crizotinib—MAP3K12—liver—obesity	0.00022	0.00162	CbGeAlD
Crizotinib—FLT3—liver—obesity	0.00022	0.00162	CbGeAlD
Crizotinib—ACVR1—liver—obesity	0.00022	0.00162	CbGeAlD
Crizotinib—EPHB6—pituitary gland—obesity	0.00022	0.00161	CbGeAlD
Crizotinib—EPHB6—adipose tissue—obesity	0.000219	0.00161	CbGeAlD
Crizotinib—SLK—adrenal gland—obesity	0.000217	0.00159	CbGeAlD
Crizotinib—Body temperature increased—Orlistat—obesity	0.000216	0.00192	CcSEcCtD
Crizotinib—STK35—liver—obesity	0.000216	0.00158	CbGeAlD
Crizotinib—EPHB4—adrenal gland—obesity	0.000215	0.00158	CbGeAlD
Crizotinib—ABL1—respiratory system—obesity	0.000214	0.00157	CbGeAlD
Crizotinib—JAK2—adrenal gland—obesity	0.000214	0.00157	CbGeAlD
Crizotinib—EPHA4—endocrine gland—obesity	0.000213	0.00156	CbGeAlD
Crizotinib—YES1—pituitary gland—obesity	0.000213	0.00156	CbGeAlD
Crizotinib—YES1—adipose tissue—obesity	0.000212	0.00155	CbGeAlD
Crizotinib—EPHA2—adrenal gland—obesity	0.000211	0.00155	CbGeAlD
Crizotinib—Bradycardia—Topiramate—obesity	0.000211	0.00187	CcSEcCtD
Crizotinib—ABL2—liver—obesity	0.00021	0.00154	CbGeAlD
Crizotinib—TAOK3—pituitary gland—obesity	0.00021	0.00154	CbGeAlD
Crizotinib—STK10—adipose tissue—obesity	0.00021	0.00154	CbGeAlD
Crizotinib—MAP3K2—endocrine gland—obesity	0.000209	0.00153	CbGeAlD
Crizotinib—TAOK3—adipose tissue—obesity	0.000209	0.00153	CbGeAlD
Crizotinib—Body temperature increased—Sibutramine—obesity	0.000209	0.00186	CcSEcCtD
Crizotinib—BMP2K—liver—obesity	0.000208	0.00152	CbGeAlD
Crizotinib—CSF1R—cardiovascular system—obesity	0.000208	0.00152	CbGeAlD
Crizotinib—Paraesthesia—Bupropion—obesity	0.000207	0.00184	CcSEcCtD
Crizotinib—TEK—adrenal gland—obesity	0.000206	0.00151	CbGeAlD
Crizotinib—MAP3K3—adrenal gland—obesity	0.000206	0.00151	CbGeAlD
Crizotinib—MAP4K5—adrenal gland—obesity	0.000206	0.00151	CbGeAlD
Crizotinib—Hypoaesthesia—Topiramate—obesity	0.000206	0.00183	CcSEcCtD
Crizotinib—Dyspnoea—Bupropion—obesity	0.000206	0.00183	CcSEcCtD
Crizotinib—PTK2—endocrine gland—obesity	0.000205	0.0015	CbGeAlD
Crizotinib—TBK1—endocrine gland—obesity	0.000205	0.0015	CbGeAlD
Crizotinib—Urinary tract disorder—Topiramate—obesity	0.000204	0.00182	CcSEcCtD
Crizotinib—SRC—adipose tissue—obesity	0.000204	0.0015	CbGeAlD
Crizotinib—Oedema peripheral—Topiramate—obesity	0.000204	0.00181	CcSEcCtD
Crizotinib—TYK2—endocrine gland—obesity	0.000204	0.00149	CbGeAlD
Crizotinib—Dyspepsia—Bupropion—obesity	0.000203	0.0018	CcSEcCtD
Crizotinib—Urethral disorder—Topiramate—obesity	0.000203	0.0018	CcSEcCtD
Crizotinib—PTK2B—liver—obesity	0.000201	0.00147	CbGeAlD
Crizotinib—Decreased appetite—Bupropion—obesity	0.0002	0.00178	CcSEcCtD
Crizotinib—YES1—digestive system—obesity	0.0002	0.00146	CbGeAlD
Crizotinib—Visual impairment—Topiramate—obesity	0.000199	0.00177	CcSEcCtD
Crizotinib—RIPK2—liver—obesity	0.000199	0.00146	CbGeAlD
Crizotinib—Gastrointestinal disorder—Bupropion—obesity	0.000199	0.00177	CcSEcCtD
Crizotinib—Fatigue—Bupropion—obesity	0.000199	0.00177	CcSEcCtD
Crizotinib—STK10—digestive system—obesity	0.000198	0.00145	CbGeAlD
Crizotinib—RPS6KB1—endocrine gland—obesity	0.000197	0.00145	CbGeAlD
Crizotinib—Constipation—Bupropion—obesity	0.000197	0.00175	CcSEcCtD
Crizotinib—TAOK3—digestive system—obesity	0.000197	0.00144	CbGeAlD
Crizotinib—EPHB6—adrenal gland—obesity	0.000197	0.00144	CbGeAlD
Crizotinib—Asthenia—Orlistat—obesity	0.000196	0.00174	CcSEcCtD
Crizotinib—FGR—endocrine gland—obesity	0.000196	0.00144	CbGeAlD
Crizotinib—AXL—endocrine gland—obesity	0.000195	0.00143	CbGeAlD
Crizotinib—Eye disorder—Topiramate—obesity	0.000193	0.00172	CcSEcCtD
Crizotinib—SRC—digestive system—obesity	0.000192	0.00141	CbGeAlD
Crizotinib—Cardiac disorder—Topiramate—obesity	0.000192	0.00171	CcSEcCtD
Crizotinib—YES1—adrenal gland—obesity	0.00019	0.00139	CbGeAlD
Crizotinib—Asthenia—Sibutramine—obesity	0.00019	0.00169	CcSEcCtD
Crizotinib—MAP3K2—liver—obesity	0.000189	0.00138	CbGeAlD
Crizotinib—STK10—adrenal gland—obesity	0.000188	0.00138	CbGeAlD
Crizotinib—TAOK3—adrenal gland—obesity	0.000188	0.00138	CbGeAlD
Crizotinib—Diarrhoea—Orlistat—obesity	0.000187	0.00166	CcSEcCtD
Crizotinib—EPHB4—endocrine gland—obesity	0.000187	0.00137	CbGeAlD
Crizotinib—Mediastinal disorder—Topiramate—obesity	0.000186	0.00166	CcSEcCtD
Crizotinib—JAK2—endocrine gland—obesity	0.000185	0.00136	CbGeAlD
Crizotinib—TBK1—liver—obesity	0.000185	0.00136	CbGeAlD
Crizotinib—PTK2—liver—obesity	0.000185	0.00136	CbGeAlD
Crizotinib—CSF1R—pituitary gland—obesity	0.000184	0.00135	CbGeAlD
Crizotinib—TYK2—liver—obesity	0.000184	0.00135	CbGeAlD
Crizotinib—CSF1R—adipose tissue—obesity	0.000183	0.00134	CbGeAlD
Crizotinib—EPHA2—endocrine gland—obesity	0.000183	0.00134	CbGeAlD
Crizotinib—SRC—adrenal gland—obesity	0.000183	0.00134	CbGeAlD
Crizotinib—Body temperature increased—Bupropion—obesity	0.000182	0.00162	CcSEcCtD
Crizotinib—IRAK1—liver—obesity	0.000181	0.00133	CbGeAlD
Crizotinib—Diarrhoea—Sibutramine—obesity	0.000181	0.00161	CcSEcCtD
Crizotinib—Dizziness—Orlistat—obesity	0.000181	0.00161	CcSEcCtD
Crizotinib—Malnutrition—Topiramate—obesity	0.00018	0.0016	CcSEcCtD
Crizotinib—ABL1—adrenal cortex—obesity	0.00018	0.00132	CbGeAlD
Crizotinib—TEK—endocrine gland—obesity	0.000179	0.00131	CbGeAlD
Crizotinib—MAP4K5—endocrine gland—obesity	0.000179	0.00131	CbGeAlD
Crizotinib—MAP3K3—endocrine gland—obesity	0.000179	0.00131	CbGeAlD
Crizotinib—RPS6KB1—liver—obesity	0.000178	0.0013	CbGeAlD
Crizotinib—LCK—liver—obesity	0.000177	0.0013	CbGeAlD
Crizotinib—FGR—liver—obesity	0.000177	0.0013	CbGeAlD
Crizotinib—Dysgeusia—Topiramate—obesity	0.000176	0.00157	CcSEcCtD
Crizotinib—AXL—liver—obesity	0.000176	0.00129	CbGeAlD
Crizotinib—Dizziness—Sibutramine—obesity	0.000175	0.00155	CcSEcCtD
Crizotinib—Vomiting—Orlistat—obesity	0.000174	0.00154	CcSEcCtD
Crizotinib—CSF1R—digestive system—obesity	0.000172	0.00126	CbGeAlD
Crizotinib—Rash—Orlistat—obesity	0.000172	0.00153	CcSEcCtD
Crizotinib—Dermatitis—Orlistat—obesity	0.000172	0.00153	CcSEcCtD
Crizotinib—Vision blurred—Topiramate—obesity	0.00017	0.00151	CcSEcCtD
Crizotinib—SLK—liver—obesity	0.000169	0.00124	CbGeAlD
Crizotinib—EPHB4—liver—obesity	0.000168	0.00123	CbGeAlD
Crizotinib—Vomiting—Sibutramine—obesity	0.000168	0.00149	CcSEcCtD
Crizotinib—JAK2—liver—obesity	0.000167	0.00122	CbGeAlD
Crizotinib—Rash—Sibutramine—obesity	0.000167	0.00148	CcSEcCtD
Crizotinib—Dermatitis—Sibutramine—obesity	0.000167	0.00148	CcSEcCtD
Crizotinib—Anaemia—Topiramate—obesity	0.000166	0.00148	CcSEcCtD
Crizotinib—Asthenia—Bupropion—obesity	0.000165	0.00147	CcSEcCtD
Crizotinib—EPHA2—liver—obesity	0.000165	0.00121	CbGeAlD
Crizotinib—YES1—endocrine gland—obesity	0.000165	0.00121	CbGeAlD
Crizotinib—CSF1R—adrenal gland—obesity	0.000164	0.0012	CbGeAlD
Crizotinib—ABL1—cardiovascular system—obesity	0.000164	0.0012	CbGeAlD
Crizotinib—STK10—endocrine gland—obesity	0.000163	0.0012	CbGeAlD
Crizotinib—TAOK3—endocrine gland—obesity	0.000163	0.00119	CbGeAlD
Crizotinib—Nausea—Orlistat—obesity	0.000162	0.00144	CcSEcCtD
Crizotinib—Syncope—Topiramate—obesity	0.000161	0.00143	CcSEcCtD
Crizotinib—Leukopenia—Topiramate—obesity	0.000161	0.00143	CcSEcCtD
Crizotinib—MAP3K3—liver—obesity	0.000161	0.00118	CbGeAlD
Crizotinib—TEK—liver—obesity	0.000161	0.00118	CbGeAlD
Crizotinib—MAP4K5—liver—obesity	0.000161	0.00118	CbGeAlD
Crizotinib—SRC—endocrine gland—obesity	0.000159	0.00116	CbGeAlD
Crizotinib—Loss of consciousness—Topiramate—obesity	0.000158	0.00141	CcSEcCtD
Crizotinib—Diarrhoea—Bupropion—obesity	0.000158	0.0014	CcSEcCtD
Crizotinib—Nausea—Sibutramine—obesity	0.000157	0.0014	CcSEcCtD
Crizotinib—Dizziness—Bupropion—obesity	0.000153	0.00136	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Topiramate—obesity	0.000152	0.00135	CcSEcCtD
Crizotinib—YES1—liver—obesity	0.000149	0.00109	CbGeAlD
Crizotinib—STK10—liver—obesity	0.000147	0.00108	CbGeAlD
Crizotinib—Oedema—Topiramate—obesity	0.000147	0.00131	CcSEcCtD
Crizotinib—TAOK3—liver—obesity	0.000147	0.00108	CbGeAlD
Crizotinib—Vomiting—Bupropion—obesity	0.000147	0.0013	CcSEcCtD
Crizotinib—Infection—Topiramate—obesity	0.000146	0.0013	CcSEcCtD
Crizotinib—Rash—Bupropion—obesity	0.000145	0.00129	CcSEcCtD
Crizotinib—ABL1—pituitary gland—obesity	0.000145	0.00107	CbGeAlD
Crizotinib—Dermatitis—Bupropion—obesity	0.000145	0.00129	CcSEcCtD
Crizotinib—ABL1—adipose tissue—obesity	0.000145	0.00106	CbGeAlD
Crizotinib—Shock—Topiramate—obesity	0.000145	0.00128	CcSEcCtD
Crizotinib—Nervous system disorder—Topiramate—obesity	0.000144	0.00128	CcSEcCtD
Crizotinib—SRC—liver—obesity	0.000143	0.00105	CbGeAlD
Crizotinib—Skin disorder—Topiramate—obesity	0.000143	0.00127	CcSEcCtD
Crizotinib—CSF1R—endocrine gland—obesity	0.000142	0.00104	CbGeAlD
Crizotinib—Nausea—Bupropion—obesity	0.000137	0.00122	CcSEcCtD
Crizotinib—ABL1—digestive system—obesity	0.000136	0.000999	CbGeAlD
Crizotinib—CYP3A5—islet of Langerhans—obesity	0.000133	0.000974	CbGeAlD
Crizotinib—Paraesthesia—Topiramate—obesity	0.000132	0.00117	CcSEcCtD
Crizotinib—Dyspnoea—Topiramate—obesity	0.000131	0.00116	CcSEcCtD
Crizotinib—ABL1—adrenal gland—obesity	0.00013	0.000952	CbGeAlD
Crizotinib—Dyspepsia—Topiramate—obesity	0.000129	0.00115	CcSEcCtD
Crizotinib—CSF1R—liver—obesity	0.000128	0.000941	CbGeAlD
Crizotinib—Decreased appetite—Topiramate—obesity	0.000128	0.00114	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Topiramate—obesity	0.000127	0.00113	CcSEcCtD
Crizotinib—Fatigue—Topiramate—obesity	0.000127	0.00113	CcSEcCtD
Crizotinib—Constipation—Topiramate—obesity	0.000126	0.00112	CcSEcCtD
Crizotinib—CYP3A5—respiratory system—obesity	0.000125	0.00092	CbGeAlD
Crizotinib—Body temperature increased—Topiramate—obesity	0.000116	0.00103	CcSEcCtD
Crizotinib—ABL1—endocrine gland—obesity	0.000113	0.000825	CbGeAlD
Crizotinib—Asthenia—Topiramate—obesity	0.000105	0.000937	CcSEcCtD
Crizotinib—ABL1—liver—obesity	0.000102	0.000744	CbGeAlD
Crizotinib—Diarrhoea—Topiramate—obesity	0.000101	0.000893	CcSEcCtD
Crizotinib—Dizziness—Topiramate—obesity	9.72e-05	0.000864	CcSEcCtD
Crizotinib—Vomiting—Topiramate—obesity	9.34e-05	0.00083	CcSEcCtD
Crizotinib—Rash—Topiramate—obesity	9.26e-05	0.000823	CcSEcCtD
Crizotinib—Dermatitis—Topiramate—obesity	9.26e-05	0.000823	CcSEcCtD
Crizotinib—Nausea—Topiramate—obesity	8.73e-05	0.000776	CcSEcCtD
Crizotinib—CYP3A5—adipose tissue—obesity	8.47e-05	0.000621	CbGeAlD
Crizotinib—CYP3A5—digestive system—obesity	7.98e-05	0.000585	CbGeAlD
Crizotinib—ABCB1—islet of Langerhans—obesity	7.06e-05	0.000517	CbGeAlD
Crizotinib—ABCB1—respiratory system—obesity	6.67e-05	0.000489	CbGeAlD
Crizotinib—CYP3A5—endocrine gland—obesity	6.59e-05	0.000483	CbGeAlD
Crizotinib—CYP3A4—digestive system—obesity	5.99e-05	0.000439	CbGeAlD
Crizotinib—CYP3A5—liver—obesity	5.94e-05	0.000436	CbGeAlD
Crizotinib—ABCB1—adrenal cortex—obesity	5.59e-05	0.00041	CbGeAlD
Crizotinib—ABCB1—cardiovascular system—obesity	5.1e-05	0.000374	CbGeAlD
Crizotinib—CYP3A4—endocrine gland—obesity	4.95e-05	0.000363	CbGeAlD
Crizotinib—ABCB1—pituitary gland—obesity	4.52e-05	0.000331	CbGeAlD
Crizotinib—ABCB1—adipose tissue—obesity	4.5e-05	0.00033	CbGeAlD
Crizotinib—CYP3A4—liver—obesity	4.46e-05	0.000327	CbGeAlD
Crizotinib—ABCB1—digestive system—obesity	4.24e-05	0.000311	CbGeAlD
Crizotinib—ABCB1—adrenal gland—obesity	4.04e-05	0.000296	CbGeAlD
Crizotinib—ABCB1—endocrine gland—obesity	3.5e-05	0.000257	CbGeAlD
Crizotinib—ABCB1—liver—obesity	3.16e-05	0.000231	CbGeAlD
Crizotinib—CYP3A4—Metabolism—CLOCK—obesity	7.12e-07	3.24e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SLC22A1—obesity	7.12e-07	3.24e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PTGS2—obesity	7.1e-07	3.23e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—RHOA—obesity	7.08e-07	3.23e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—POMC—obesity	7.04e-07	3.21e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NOS3—obesity	7.01e-07	3.19e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PIK3R1—obesity	7.01e-07	3.19e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—INS—obesity	7e-07	3.19e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—AGT—obesity	6.94e-07	3.16e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SULT2A1—obesity	6.94e-07	3.16e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GLP1R—obesity	6.94e-07	3.16e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ESR1—obesity	6.93e-07	3.15e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MTOR—obesity	6.91e-07	3.15e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PIK3CB—obesity	6.91e-07	3.15e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—PIK3CA—obesity	6.89e-07	3.14e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCL2—obesity	6.89e-07	3.14e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—F2—obesity	6.84e-07	3.12e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PRKCB—obesity	6.84e-07	3.12e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—DPYD—obesity	6.82e-07	3.11e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—COMT—obesity	6.82e-07	3.11e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—APOE—obesity	6.8e-07	3.1e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—STAT3—obesity	6.8e-07	3.09e-06	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—AKT1—obesity	6.77e-07	3.08e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—STAT3—obesity	6.77e-07	3.08e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IGF1—obesity	6.77e-07	3.08e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AKT2—obesity	6.77e-07	3.08e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—BAD—obesity	6.76e-07	3.08e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MYC—obesity	6.75e-07	3.07e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CAV1—obesity	6.74e-07	3.07e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TGFB1—obesity	6.74e-07	3.07e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GNB3—obesity	6.73e-07	3.06e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PPARGC1A—obesity	6.73e-07	3.06e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—APOA1—obesity	6.72e-07	3.06e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—HMOX1—obesity	6.7e-07	3.05e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—AKT1—obesity	6.69e-07	3.05e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—PIK3CA—obesity	6.68e-07	3.04e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—PIK3CA—obesity	6.68e-07	3.04e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MYC—obesity	6.66e-07	3.03e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TGFB1—obesity	6.64e-07	3.02e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—MYC—obesity	6.63e-07	3.02e-06	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—AKT1—obesity	6.63e-07	3.02e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—TGFB1—obesity	6.62e-07	3.01e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—STAT3—obesity	6.6e-07	3e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—IL6—obesity	6.58e-07	3e-06	CbGpPWpGaD
Crizotinib—TYK2—Immune System—AKT1—obesity	6.58e-07	2.99e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PRKAR2B—obesity	6.57e-07	2.99e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—MAPK8—obesity	6.56e-07	2.99e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GNAS—obesity	6.55e-07	2.98e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CG—obesity	6.55e-07	2.98e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—DCN—obesity	6.52e-07	2.97e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—PIK3CA—obesity	6.52e-07	2.97e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CD—obesity	6.5e-07	2.96e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—PIK3CA—obesity	6.49e-07	2.95e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IRS1—obesity	6.47e-07	2.95e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MTOR—obesity	6.47e-07	2.95e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PIK3CB—obesity	6.47e-07	2.95e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IL6—obesity	6.47e-07	2.95e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SERPINE1—obesity	6.43e-07	2.93e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—APOB—obesity	6.41e-07	2.92e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IL6—obesity	6.37e-07	2.9e-06	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—AKT1—obesity	6.37e-07	2.9e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CPT1A—obesity	6.34e-07	2.89e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MYC—obesity	6.32e-07	2.88e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TGFB1—obesity	6.3e-07	2.87e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TYK2—obesity	6.25e-07	2.85e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—STAT3—obesity	6.25e-07	2.85e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—POMC—obesity	6.23e-07	2.84e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NAMPT—obesity	6.22e-07	2.83e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—RHOA—obesity	6.2e-07	2.82e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—INS—obesity	6.2e-07	2.82e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—LIPC—obesity	6.18e-07	2.82e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GCK—obesity	6.18e-07	2.82e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—APOC3—obesity	6.14e-07	2.8e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NOS3—obesity	6.14e-07	2.8e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3R1—obesity	6.14e-07	2.8e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CG—obesity	6.14e-07	2.8e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MYC—obesity	6.13e-07	2.79e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—LPL—obesity	6.12e-07	2.79e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TGFB1—obesity	6.12e-07	2.78e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—PIK3CA—obesity	6.1e-07	2.78e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL6—obesity	6.1e-07	2.78e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCL2—obesity	6.1e-07	2.78e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—AKT1—obesity	6.07e-07	2.76e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MMP9—obesity	6.01e-07	2.74e-06	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—AKT1—obesity	6.01e-07	2.74e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—STAT3—obesity	6e-07	2.73e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IGF1—obesity	5.99e-07	2.73e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AKT2—obesity	5.99e-07	2.73e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GPX1—obesity	5.97e-07	2.72e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—AKT1—obesity	5.97e-07	2.72e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CETP—obesity	5.96e-07	2.72e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PPARG—obesity	5.92e-07	2.7e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL6—obesity	5.92e-07	2.69e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL6—obesity	5.91e-07	2.69e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SDC1—obesity	5.9e-07	2.69e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—AKT1—obesity	5.88e-07	2.68e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MAPK8—obesity	5.84e-07	2.66e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—POMC—obesity	5.84e-07	2.66e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CD36—obesity	5.82e-07	2.65e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MYC—obesity	5.81e-07	2.65e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—INS—obesity	5.81e-07	2.65e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AKR1C3—obesity	5.8e-07	2.64e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—TGFB1—obesity	5.8e-07	2.64e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL6—obesity	5.77e-07	2.63e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CD—obesity	5.76e-07	2.62e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL6—obesity	5.75e-07	2.62e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—PIK3CA—obesity	5.73e-07	2.61e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SCARB1—obesity	5.71e-07	2.6e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—SERPINE1—obesity	5.69e-07	2.59e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CB—obesity	5.67e-07	2.58e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MTOR—obesity	5.67e-07	2.58e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—PIK3CA—obesity	5.65e-07	2.57e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—PIK3CA—obesity	5.63e-07	2.56e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—AKT1—obesity	5.63e-07	2.56e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MMP9—obesity	5.62e-07	2.56e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SREBF1—obesity	5.55e-07	2.53e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TYK2—obesity	5.54e-07	2.52e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—STAT3—obesity	5.54e-07	2.52e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—MTHFR—obesity	5.51e-07	2.51e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—RHOA—obesity	5.49e-07	2.5e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MAPK8—obesity	5.47e-07	2.49e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—AKT1—obesity	5.46e-07	2.48e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—AKT1—obesity	5.45e-07	2.48e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3R1—obesity	5.43e-07	2.47e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NOS3—obesity	5.43e-07	2.47e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PPARA—obesity	5.41e-07	2.46e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL6—obesity	5.4e-07	2.46e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CD—obesity	5.4e-07	2.46e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GOT2—obesity	5.39e-07	2.46e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—PIK3CA—obesity	5.36e-07	2.44e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—PIK3CA—obesity	5.34e-07	2.43e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—STAT3—obesity	5.34e-07	2.43e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ALB—obesity	5.33e-07	2.43e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—AKT1—obesity	5.33e-07	2.42e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—AKT1—obesity	5.3e-07	2.41e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—FASN—obesity	5.28e-07	2.4e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—BCHE—obesity	5.26e-07	2.39e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—AGT—obesity	5.24e-07	2.39e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—PIK3CA—obesity	5.2e-07	2.37e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MYC—obesity	5.14e-07	2.34e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—APOE—obesity	5.13e-07	2.34e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—TGFB1—obesity	5.13e-07	2.34e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3R1—obesity	5.1e-07	2.32e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—NOS3—obesity	5.1e-07	2.32e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CAV1—obesity	5.09e-07	2.32e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL6—obesity	5.08e-07	2.31e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—APOA1—obesity	5.07e-07	2.31e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP2E1—obesity	5.07e-07	2.31e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MTOR—obesity	5.02e-07	2.28e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CB—obesity	5.02e-07	2.28e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NQO1—obesity	5.01e-07	2.28e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL6—obesity	5.01e-07	2.28e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—STAT3—obesity	5e-07	2.28e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—IL6—obesity	4.99e-07	2.27e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—AKT1—obesity	4.98e-07	2.27e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MYC—obesity	4.96e-07	2.26e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TGFB1—obesity	4.95e-07	2.26e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—PIK3CA—obesity	4.93e-07	2.25e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MMP9—obesity	4.93e-07	2.24e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GCG—obesity	4.81e-07	2.19e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SLC2A4—obesity	4.81e-07	2.19e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MAPK8—obesity	4.79e-07	2.18e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL6—obesity	4.75e-07	2.16e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYCS—obesity	4.75e-07	2.16e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL6—obesity	4.73e-07	2.15e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—PIK3CA—obesity	4.73e-07	2.15e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CB—obesity	4.7e-07	2.14e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—AKT1—obesity	4.68e-07	2.13e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTGS2—obesity	4.66e-07	2.12e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GGT1—obesity	4.66e-07	2.12e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GOT1—obesity	4.66e-07	2.12e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MYC—obesity	4.65e-07	2.12e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TGFB1—obesity	4.63e-07	2.11e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CG—obesity	4.63e-07	2.11e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—AKT1—obesity	4.62e-07	2.1e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL6—obesity	4.61e-07	2.1e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—AKT1—obesity	4.6e-07	2.1e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NCOA1—obesity	4.59e-07	2.09e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—STK11—obesity	4.52e-07	2.06e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP19A1—obesity	4.52e-07	2.06e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PPARG—obesity	4.47e-07	2.04e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—POMC—obesity	4.41e-07	2.01e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—INS—obesity	4.39e-07	2e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—AKT1—obesity	4.38e-07	1.99e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—STAT3—obesity	4.38e-07	1.99e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—IL6—obesity	4.37e-07	1.99e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PIK3CA—obesity	4.37e-07	1.99e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—AKT1—obesity	4.36e-07	1.99e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MMP9—obesity	4.36e-07	1.99e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—AKT1—obesity	4.25e-07	1.94e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MAPK8—obesity	4.24e-07	1.93e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PIK3CA—obesity	4.21e-07	1.92e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—COMT—obesity	4.2e-07	1.91e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL6—obesity	4.19e-07	1.91e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GNB3—obesity	4.14e-07	1.89e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PPARGC1A—obesity	4.14e-07	1.89e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—HMOX1—obesity	4.12e-07	1.88e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CD—obesity	4.07e-07	1.85e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MYC—obesity	4.07e-07	1.85e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TGFB1—obesity	4.06e-07	1.85e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GNAS—obesity	4.03e-07	1.84e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—AKT1—obesity	4.03e-07	1.84e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ALB—obesity	4.02e-07	1.83e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—APOB—obesity	3.95e-07	1.8e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PIK3CA—obesity	3.94e-07	1.8e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—STAT3—obesity	3.88e-07	1.77e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—IL6—obesity	3.87e-07	1.76e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—AKT1—obesity	3.86e-07	1.76e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3R1—obesity	3.85e-07	1.75e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—NOS3—obesity	3.85e-07	1.75e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—LPL—obesity	3.77e-07	1.72e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL6—obesity	3.73e-07	1.7e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GPX1—obesity	3.68e-07	1.68e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MYC—obesity	3.6e-07	1.64e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TGFB1—obesity	3.59e-07	1.64e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CD36—obesity	3.58e-07	1.63e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—AKT1—obesity	3.57e-07	1.62e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CB—obesity	3.55e-07	1.62e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTGS2—obesity	3.52e-07	1.6e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL6—obesity	3.49e-07	1.59e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CA—obesity	3.45e-07	1.57e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—AKT1—obesity	3.44e-07	1.57e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MTHFR—obesity	3.4e-07	1.55e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PPARA—obesity	3.33e-07	1.52e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AGT—obesity	3.23e-07	1.47e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AKT1—obesity	3.22e-07	1.47e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—APOE—obesity	3.16e-07	1.44e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CAV1—obesity	3.13e-07	1.43e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—APOA1—obesity	3.13e-07	1.42e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL6—obesity	3.06e-07	1.39e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CA—obesity	3.06e-07	1.39e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CA—obesity	2.87e-07	1.31e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CG—obesity	2.85e-07	1.3e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AKT1—obesity	2.82e-07	1.29e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PPARG—obesity	2.75e-07	1.25e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—POMC—obesity	2.72e-07	1.24e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6—obesity	2.71e-07	1.23e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—INS—obesity	2.7e-07	1.23e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CD—obesity	2.51e-07	1.14e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AKT1—obesity	2.5e-07	1.14e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ALB—obesity	2.48e-07	1.13e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3R1—obesity	2.37e-07	1.08e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NOS3—obesity	2.37e-07	1.08e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—AKT1—obesity	2.34e-07	1.07e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CB—obesity	2.19e-07	9.96e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTGS2—obesity	2.17e-07	9.87e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CA—obesity	2.16e-07	9.85e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—AKT1—obesity	1.77e-07	8.05e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CA—obesity	1.33e-07	6.07e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AKT1—obesity	1.09e-07	4.96e-07	CbGpPWpGaD
